Walking the Tightrope: Optimising Blood Thinner Timing After Brain Surgery

Chronic subdural haematoma (CSDH)—a collection of blood on the brain's surface—is a rapidly growing condition, largely driven by an ageing population. For the 25% of these patients who also suffer from atrial fibrillation (an irregular heartbeat requiring blood thinners), surgery presents a precarious balancing act. Surgeons must decide when to restart anticoagulants: too soon, and the brain might bleed again; too late, and the patient risks a stroke or blood clot. Currently, no solid evidence guides this decision.

Enter the RELACS trial, the first large-scale, international, randomised controlled study designed to fill this gap. Researchers plan to recruit approximately 332 patients to compare two distinct strategies: an 'early' resumption of medication just five days post-surgery versus a 'late' return at thirty days. The team hypothesises that restarting therapy early will prevent dangerous clotting events without triggering fresh haemorrhagic complications. If successful, this phase III trial could finally provide a standard of care for managing this high-stakes clinical puzzle.